Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X–linked Hypophosphatemia (XLH) in Adults and Children

World News: . []

NOVATO Calif TOKYO and LONDON Dec 06 2018 GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc NASDAQ RARE a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases Kyowa Hak ko Kiri...

More news and information about Ultragenyx Pharmaceutical Inc.

Published By:

Globe Newswire: 13:30 GMT Thursday 6th December 2018

Published: .

Search for other references to "ultragenyx" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us